Cargando…
A Preliminary Inquiry Into the Potential Mechanism of Huang-Lian-Jie-Du Decoction in Treating Rheumatoid Arthritis via Network Pharmacology and Molecular Docking
Huang-Lian-Jie-Du decoction (HLJDD) has been widely applied to treat inflammation-associated diseases for thousands of years in China. However, the concrete molecular mechanism of HLJDD in the treatment of rheumatoid arthritis (RA) remains unclear. In this work, network pharmacology and molecular do...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807552/ https://www.ncbi.nlm.nih.gov/pubmed/35127697 http://dx.doi.org/10.3389/fcell.2021.740266 |
_version_ | 1784643703533469696 |
---|---|
author | Li, Chenlu Pan, Jingjing Xu, Chang Jin, Zhenlin Chen, Xupeng |
author_facet | Li, Chenlu Pan, Jingjing Xu, Chang Jin, Zhenlin Chen, Xupeng |
author_sort | Li, Chenlu |
collection | PubMed |
description | Huang-Lian-Jie-Du decoction (HLJDD) has been widely applied to treat inflammation-associated diseases for thousands of years in China. However, the concrete molecular mechanism of HLJDD in the treatment of rheumatoid arthritis (RA) remains unclear. In this work, network pharmacology and molecular docking were applied to preliminarily analyze the potential active ingredients, drug targets, and related pathways of HLJDD on treating RA. A total of 102 active compounds with corresponding 189 targets were identified from HLJDD, and 41 common targets were further identified by intersecting with RA-related targets. Functional enrichment analysis was performed to screen the biological pathways associated with RA. Ten hub targets were further identified through constructing the protein–protein interaction (PPI) network of common targets, which were mainly enriched in the interleukin-17 (IL-17) signaling pathway, tumor necrosis factor (TNF) signaling pathway, and Toll-like receptor signaling pathway. Furthermore, a complex botanical drugs-ingredients-hub-targets-disease network was successfully constructed. The molecular docking results exhibited that these vital ingredients of HLJDD had a stable binding to the hub targets. Among these ingredients, quercetin (MOL000098) was the most common molecule with stable binding to all the targets, and PTGS2 was considered the most important target with multiple regulations by the most active ingredients. In vitro, we successfully validated the inhibitory role of quercetin in the cellular proliferation of human RA fibroblast-like synoviocyte cell line (MH7A cells). These findings indicated that the potential mechanisms of HLJDD for RA treatment might be attributed to inhibiting the immune-inflammatory response, reducing the release of chemokines, and alleviating the destruction of extracellular matrix (ECM) in the synovial compartment. |
format | Online Article Text |
id | pubmed-8807552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88075522022-02-03 A Preliminary Inquiry Into the Potential Mechanism of Huang-Lian-Jie-Du Decoction in Treating Rheumatoid Arthritis via Network Pharmacology and Molecular Docking Li, Chenlu Pan, Jingjing Xu, Chang Jin, Zhenlin Chen, Xupeng Front Cell Dev Biol Cell and Developmental Biology Huang-Lian-Jie-Du decoction (HLJDD) has been widely applied to treat inflammation-associated diseases for thousands of years in China. However, the concrete molecular mechanism of HLJDD in the treatment of rheumatoid arthritis (RA) remains unclear. In this work, network pharmacology and molecular docking were applied to preliminarily analyze the potential active ingredients, drug targets, and related pathways of HLJDD on treating RA. A total of 102 active compounds with corresponding 189 targets were identified from HLJDD, and 41 common targets were further identified by intersecting with RA-related targets. Functional enrichment analysis was performed to screen the biological pathways associated with RA. Ten hub targets were further identified through constructing the protein–protein interaction (PPI) network of common targets, which were mainly enriched in the interleukin-17 (IL-17) signaling pathway, tumor necrosis factor (TNF) signaling pathway, and Toll-like receptor signaling pathway. Furthermore, a complex botanical drugs-ingredients-hub-targets-disease network was successfully constructed. The molecular docking results exhibited that these vital ingredients of HLJDD had a stable binding to the hub targets. Among these ingredients, quercetin (MOL000098) was the most common molecule with stable binding to all the targets, and PTGS2 was considered the most important target with multiple regulations by the most active ingredients. In vitro, we successfully validated the inhibitory role of quercetin in the cellular proliferation of human RA fibroblast-like synoviocyte cell line (MH7A cells). These findings indicated that the potential mechanisms of HLJDD for RA treatment might be attributed to inhibiting the immune-inflammatory response, reducing the release of chemokines, and alleviating the destruction of extracellular matrix (ECM) in the synovial compartment. Frontiers Media S.A. 2022-01-19 /pmc/articles/PMC8807552/ /pubmed/35127697 http://dx.doi.org/10.3389/fcell.2021.740266 Text en Copyright © 2022 Li, Pan, Xu, Jin and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Li, Chenlu Pan, Jingjing Xu, Chang Jin, Zhenlin Chen, Xupeng A Preliminary Inquiry Into the Potential Mechanism of Huang-Lian-Jie-Du Decoction in Treating Rheumatoid Arthritis via Network Pharmacology and Molecular Docking |
title | A Preliminary Inquiry Into the Potential Mechanism of Huang-Lian-Jie-Du Decoction in Treating Rheumatoid Arthritis via Network Pharmacology and Molecular Docking |
title_full | A Preliminary Inquiry Into the Potential Mechanism of Huang-Lian-Jie-Du Decoction in Treating Rheumatoid Arthritis via Network Pharmacology and Molecular Docking |
title_fullStr | A Preliminary Inquiry Into the Potential Mechanism of Huang-Lian-Jie-Du Decoction in Treating Rheumatoid Arthritis via Network Pharmacology and Molecular Docking |
title_full_unstemmed | A Preliminary Inquiry Into the Potential Mechanism of Huang-Lian-Jie-Du Decoction in Treating Rheumatoid Arthritis via Network Pharmacology and Molecular Docking |
title_short | A Preliminary Inquiry Into the Potential Mechanism of Huang-Lian-Jie-Du Decoction in Treating Rheumatoid Arthritis via Network Pharmacology and Molecular Docking |
title_sort | preliminary inquiry into the potential mechanism of huang-lian-jie-du decoction in treating rheumatoid arthritis via network pharmacology and molecular docking |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807552/ https://www.ncbi.nlm.nih.gov/pubmed/35127697 http://dx.doi.org/10.3389/fcell.2021.740266 |
work_keys_str_mv | AT lichenlu apreliminaryinquiryintothepotentialmechanismofhuanglianjiedudecoctionintreatingrheumatoidarthritisvianetworkpharmacologyandmoleculardocking AT panjingjing apreliminaryinquiryintothepotentialmechanismofhuanglianjiedudecoctionintreatingrheumatoidarthritisvianetworkpharmacologyandmoleculardocking AT xuchang apreliminaryinquiryintothepotentialmechanismofhuanglianjiedudecoctionintreatingrheumatoidarthritisvianetworkpharmacologyandmoleculardocking AT jinzhenlin apreliminaryinquiryintothepotentialmechanismofhuanglianjiedudecoctionintreatingrheumatoidarthritisvianetworkpharmacologyandmoleculardocking AT chenxupeng apreliminaryinquiryintothepotentialmechanismofhuanglianjiedudecoctionintreatingrheumatoidarthritisvianetworkpharmacologyandmoleculardocking AT lichenlu preliminaryinquiryintothepotentialmechanismofhuanglianjiedudecoctionintreatingrheumatoidarthritisvianetworkpharmacologyandmoleculardocking AT panjingjing preliminaryinquiryintothepotentialmechanismofhuanglianjiedudecoctionintreatingrheumatoidarthritisvianetworkpharmacologyandmoleculardocking AT xuchang preliminaryinquiryintothepotentialmechanismofhuanglianjiedudecoctionintreatingrheumatoidarthritisvianetworkpharmacologyandmoleculardocking AT jinzhenlin preliminaryinquiryintothepotentialmechanismofhuanglianjiedudecoctionintreatingrheumatoidarthritisvianetworkpharmacologyandmoleculardocking AT chenxupeng preliminaryinquiryintothepotentialmechanismofhuanglianjiedudecoctionintreatingrheumatoidarthritisvianetworkpharmacologyandmoleculardocking |